Experimental evaluation of ebastine, a second-generation anti-histamine, as a supportive medication for alopecia areata

The study evaluated the use of ebastine, a second-generation anti-histamine, as a supportive treatment for alopecia areata (AA). Ebastine, known for its role in treating allergic conditions, was found to promote hair regrowth in patients with intractable AA. Two case studies were highlighted: a 25-year-old female with atopic dermatitis and a 40-year-old female with progressive AA, both of whom showed significant improvement after ebastine treatment. The drug's ability to suppress Th2-type proinflammatory cytokines and inhibit T cell migration was suggested as a mechanism for its effectiveness, given the T cell-mediated inflammatory destruction observed in AA.